Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Xu, Cheng Shi ^a   Wang, Ze Fen ^b   Dai, Li Ming ^a   Chu, Sheng Hua ^c   Gong, Ling Ling ^a   Yang, Ming Huan ^a   Li, Zhi Qiang ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c School of Medicine   (China)

Author keywords

Anti VEGF; Focal adhesion kinase; Glioma; Invasion; Proline rich tyrosine kinase

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; BEVACIZUMAB; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MTT ASSAY; NONHUMAN; RAT; TUMOR INVASION; ANIMAL; BRAIN NEOPLASMS; ENZYMOLOGY; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; ENZYME INDUCTION; FOCAL ADHESION KINASE 2; GLIOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RATS;

EID: 84902073282     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-148     Document Type: Article

References (38)

1. Yamanaka R, Saya H. Molecularly targeted therapies for glioma. Ann Neurol 2009, 66:717-729. 10.1002/ana.21793, 20035507.
2. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610-622.
3. Li Z, Wang J, Gong L, Wen Z, Xu C, Huang X. Correlation of Delta-like ligand 4 (DLL4) with VEGF and HIF-1alpha expression in human glioma. Asian Pac J Cancer Prev 2011, 12:215-218.
4. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009, 5:610-620. 10.1038/nrneurol.2009.159, 19826401.
5. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740. 10.1200/JCO.2008.19.8721, 19720927.
6. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729. 10.1200/JCO.2007.12.2440, 17947719.
7. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011, 29:142-148. 10.1200/JCO.2010.30.2729, 3058273, 21135282.
8. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011, 6:2. 10.1186/1748-717X-6-2, 3025871, 21214925.
9. Chinot OL, de La Motte RT, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011, 28:334-340. 10.1007/s12325-011-0007-3, 21432029.
10. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014, 370:699-708. 10.1056/NEJMoa1308573, 24552317.
11. Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol 2008, 10:700-708. 10.1215/15228517-2008-042, 2666246, 18697955.
12. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008, 7:1152-1160. 10.1016/S1474-4422(08)70260-6, 19007739.
13. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009, 15:4589-4599. 10.1158/1078-0432.CCR-09-0575, 19567589.
14. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010, 12:233-242. 10.1093/neuonc/nop027, 2940588, 20167811.
15. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787. 10.1212/01.wnl.0000304121.57857.38, 18316689.
16. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231. 10.1016/j.ccr.2009.01.027, 2874829, 19249680.
17. Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011, 28:13-24. 10.1007/s10014-010-0007-z, 21221826.
18. Sakamoto Y, Ogita H, Hirota T, Kawakatsu T, Fukuyama T, Yasumi M, Kanzaki N, Ozaki M, Takai Y. Interaction of integrin alpha(v)beta3 with nectin. Implication in cross-talk between cell-matrix and cell-cell junctions. J Biol Chem 2006, 281:19631-19644. 10.1074/jbc.M600301200, 16679515.
19. Fisher KD, Codina J, Petrovic S, DuBose TD. Pyk2 regulates H + -ATPase-mediated proton secretion in the outer medullary collecting duct via an ERK1/2 signaling pathway. Am J Physiol Renal Physiol 2012, 303:F1353-F1362. 10.1152/ajprenal.00008.2012, 3518186, 22811489.
20. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal 2000, 12:123-133. 10.1016/S0898-6568(99)00076-5, 10704819.
21. Gutenberg A, Bruck W, Buchfelder M, Ludwig HC. Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas. Acta Neuropathol 2004, 108:224-230.
22. Wu ZM, Yuan XH, Jiang PC, Li ZQ, Wu T. Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells. J Neurooncol 2006, 77:117-123. 10.1007/s11060-005-9025-9, 16314954.
23. Li Z, Yuan X, Wu Z, Guo Z, Jiang P, Wen Z. Expressions of FAK and Pyk2 in human astrocytic tumors and their relationship with angiogenesis. Chin Ger J Clin Oncol 2008, 7:658-660.
24. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res 2013, 73:3145-3154. 10.1158/0008-5472.CAN-13-0011, 4040366, 23644530.
25. Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, Cao S, Lin X. Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One 2011, 6:e16264. 10.1371/journal.pone.0016264, 3021542, 21264258.
26. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011, 108:3749-3754. 10.1073/pnas.1014480108, 3048093, 21321221.
27. Aaberg-Jessen C, Norregaard A, Christensen K, Pedersen CB, Andersen C, Kristensen BW. Invasion of primary glioma- and cell line-derived spheroids implanted into corticostriatal slice cultures. Int J Clin Exp Pathol 2013, 6:546-560. 3606845, 23573302.
28. Lin AH, Eliceiri BP, Levin EG. FAK mediates the inhibition of glioma cell migration by truncated 24 kDa FGF-2. Biochem Biophys Res Commun 2009, 382:503-507. 10.1016/j.bbrc.2009.03.084, 3426351, 19303400.
29. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239. 10.1016/j.ccr.2009.01.021, 19249681.
30. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61:6624-6628.
31. Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics 2009, 6:447-457. 10.1016/j.nurt.2009.04.001, 19560735.
32. Al-Zahrani KN, Baron KD, Sabourin LA. Ste20-like kinase SLK, at the crossroads: a matter of life and death. Cell Adh Migr 2013, 7:1-10. 10.4161/cam.22495, 3544772, 23154402.
33. Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 2010, 123:1007-1013. 10.1242/jcs.045112, 20332118.
34. Lipinski CA, Tran NL, Bay C, Kloss J, McDonough WS, Beaudry C, Berens ME, Loftus JC. Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. Mol Cancer Res 2003, 1:323-332.
35. Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY. HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 2013, 123:2078-2093. 10.1172/JCI66715, 3635738, 23563312.
36. Kostourou V, Lechertier T, Reynolds LE, Lees DM, Baker M, Jones DT, Tavora B, Ramjaun AR, Birdsey GM, Robinson SD, Parsons M, Randi AM, Hart IR, Hodivala-Dilke K. FAK-heterozygous mice display enhanced tumour angiogenesis. Nat Commun 2013, 4:2020. 3712492, 23799510.
37. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloeguen Y, Cloughesy TF. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 2013, 13:347. 3631110, 23529375.
38. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972. 10.1200/JCO.2009.26.3541, 20231676.